Abstract
Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Current Pharmaceutical Biotechnology
Title: Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents
Volume: 1 Issue: 3
Author(s): S. D. Nuttall, R. A. Iring and P. J. Hudson
Affiliation:
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Abstract: Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Export Options
About this article
Cite this article as:
Nuttall D. S., Iring A. R. and Hudson J. P., Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents, Current Pharmaceutical Biotechnology 2000; 1 (3) . https://dx.doi.org/10.2174/1389201003378906
DOI https://dx.doi.org/10.2174/1389201003378906 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Reviews on Recent Clinical Trials Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Bio-Activities and Syntheses Developments of Triptolides
Mini-Reviews in Organic Chemistry Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Sam Domains in Multiple Diseases
Current Medicinal Chemistry Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Current Drug Metabolism The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Biodefense Properties of Milk: The Role of Antimicrobial Proteins and Peptides
Current Pharmaceutical Design From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery
Current Topics in Medicinal Chemistry Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets In Vitro Anticancer Evaluation of Some Synthesized 2H-Quinolinone and Halogenated 2H-Quinolinone Derivatives as Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry